← ANALYSTS · TIPRANKS
Jack Allen · Robert W. Baird
Hits
30%
76 of 255 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
−16.3%
Over a year after the rating, TipRanks’ measure
Our companies rated now
8
Buy / hold / sell: 5 / 3 / 0
Upside of the analyst’s targets
+222.0%
Average over 8 current targets, to the last price
The market’s answer to the ratings
−0.6%
Day-0 move against SPY in the rating’s direction, average over 8 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Sep 3on TipRanks 05:05 | RAREIWMUltragenyx Pharmaceutical · $1.5B | Downgrade | Hold | $40.00 → $16.00−60.0% | +10.0% | −45.1%next day +3.4% · 5 days −2.6% | ↗ |
| Jun 30on TipRanks 07:16 | TSHAIWMTaysha Gene Therapies · $1.2B | Reiterated | Buy | $12.00 → $15.00+25.0% | +314.4% | +0.4%next day −2.2% · 5 days −4.5% | ↗ |
| Jun 26on TipRanks Jun 25 16:25 | FTHFaeth Therapeutics · $517M | Initiated | Buy | $57.00 | +203.2% | −6.6%next day −0.1% · 5 days +4.0% | ↗ |
| May 1on TipRanks Apr 30 16:45 | LYELIWMLyell Immunopharma · $196M | Initiated | Buy | $49.00 | +503.4% | +5.3%next day −0.2% · 5 days −9.6% | ↗ |
| Apr 27on TipRanks 12:20 | NTLAIWMIntellia Therapeutics · $1.6B | Reiterated | Hold | $7.00 → $13.00+85.7% | +13.8% | −4.5%next day +1.7% · 5 days +6.0% | ↗ |
| Apr 14on TipRanks 07:35 | ALLOIWMAllogene Therapeutics · $463M | Reiterated | Buy | $7.00 → $9.00+28.6% | +587.0% | −26.7%next day −5.6% · 5 days +0.4% | ↗ |
| Dec 23on TipRanks 07:05 | VORIWMVor Biopharma · $1.1B | Reiterated | Buy | $64.00 → $46.00−28.1% | +155.1% | −1.8%next day +7.0% · 5 days −2.4% | ↗ |
| Nov 11on TipRanks 07:35 | CRSPIWMCrispr Therapeutics AG · $5.0B | Reiterated | Hold | $52.00 → $44.00−15.4% | −10.7% | +0.9%next day −5.5% · 5 days +0.2% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗